EPLIN-β is a novel substrate of ornithine decarboxylase antizyme 1 and mediates cellular migration

Dan Li1, Suat Peng Neo2, Jayantha Gunaratne2,3

  • 1Division of Cellular & Molecular Research, Humphrey Oei Institute of Cancer Research, National Cancer Centre Singapore, Singapore 168583, Singapore.

PubMed

Insights

Ornithine decarboxylase antizyme 1 (Az1) targets epithelial protein lost in neoplasm-beta (EPLIN-β) for degradation, impacting cell migration. Elevated EPLIN-β correlates with poorer colorectal cancer survival.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Cancer Research

Background:

  • Polyamines are crucial for cellular proliferation and their levels are regulated by ornithine decarboxylase antizyme 1 (Az1).
  • Az1 mediates the degradation of substrates like ornithine decarboxylase (ODC) and cyclin D1, influencing cell growth and tumorigenesis.

Purpose of the Study:

  • To identify novel substrates of Az1 using quantitative proteomics.
  • To investigate the role of Az1-mediated protein degradation in cellular processes linked to tumorigenesis.

Main Methods:

  • Quantitative proteomics to identify Az1 substrates.
  • Analysis of Az1-EPLIN-β interaction and degradation pathway.
  • Correlation analysis of LIMA1 levels with patient survival data.

Main Results:

  • LIM domain and actin-binding protein 1 (LIMA1), or epithelial protein lost in neoplasm (EPLIN), was identified as a novel Az1 substrate.
  • Only the EPLIN-β isoform is degraded by Az1 in a ubiquitination-independent manner.
  • Az1 absence results in increased EPLIN-β levels and enhanced cellular migration; higher LIMA1 levels predict poorer colorectal cancer survival.

Conclusions:

  • Epithelial protein lost in neoplasm-beta (EPLIN-β) is a novel Az1 substrate.
  • Az1-mediated degradation of EPLIN-β regulates cellular migration.
  • LIMA1/EPLIN-β dysregulation is implicated in colorectal cancer progression.